Becton Dickinson EBITDA Margin 2010-2023 | BDX
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Becton Dickinson (BDX) over the last 10 years. The current EBITDA margin for Becton Dickinson as of December 31, 2023 is .
| Becton Dickinson EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2023-12-31 |
$19.49B |
$4.25B |
21.78% |
| 2023-09-30 |
$19.37B |
$4.40B |
22.71% |
| 2023-06-30 |
$19.05B |
$4.53B |
23.79% |
| 2023-03-31 |
$18.81B |
$4.50B |
23.95% |
| 2022-12-31 |
$18.74B |
$4.43B |
23.63% |
| 2022-09-30 |
$18.87B |
$4.51B |
23.91% |
| 2022-06-30 |
$18.41B |
$4.11B |
22.31% |
| 2022-03-31 |
$18.38B |
$4.04B |
22.01% |
| 2021-12-31 |
$18.53B |
$3.92B |
21.16% |
| 2021-09-30 |
$19.13B |
$4.48B |
23.42% |
| 2021-06-30 |
$18.57B |
$4.01B |
21.60% |
| 2021-03-31 |
$17.82B |
$3.88B |
21.76% |
| 2020-12-31 |
$17.16B |
$3.79B |
22.10% |
| 2020-09-30 |
$16.07B |
$3.03B |
18.83% |
| 2020-06-30 |
$16.92B |
$3.50B |
20.66% |
| 2020-03-31 |
$17.41B |
$3.80B |
21.83% |
| 2019-12-31 |
$17.36B |
$3.60B |
20.71% |
| 2019-09-30 |
$17.29B |
$4.01B |
23.21% |
| 2019-06-30 |
$17.11B |
$4.49B |
26.25% |
| 2019-03-31 |
$17.04B |
$4.37B |
25.65% |
| 2018-12-31 |
$17.06B |
$4.41B |
25.85% |
| 2018-09-30 |
$15.98B |
$3.49B |
21.82% |
| 2018-06-30 |
$14.75B |
$3.12B |
21.17% |
| 2018-03-31 |
$13.50B |
$2.10B |
15.54% |
| 2017-12-31 |
$12.25B |
$2.06B |
16.85% |
| 2017-09-30 |
$12.09B |
$2.61B |
21.58% |
| 2017-06-30 |
$12.16B |
$2.20B |
18.12% |
| 2017-03-31 |
$12.32B |
$2.94B |
23.83% |
| 2016-12-31 |
$12.42B |
$2.98B |
23.96% |
| 2016-09-30 |
$12.48B |
$2.54B |
20.38% |
| 2016-06-30 |
$12.31B |
$2.78B |
22.61% |
| 2016-03-31 |
$12.23B |
$2.43B |
19.88% |
| 2015-12-31 |
$11.22B |
$2.12B |
18.88% |
| 2015-09-30 |
$10.28B |
$1.97B |
19.11% |
| 2015-06-30 |
$9.42B |
$1.91B |
20.21% |
| 2015-03-31 |
$8.46B |
$2.06B |
24.30% |
| 2014-12-31 |
$8.48B |
$2.14B |
25.18% |
| 2014-09-30 |
$8.45B |
$2.17B |
25.67% |
| 2014-06-30 |
$8.35B |
$1.84B |
22.01% |
| 2014-03-31 |
$8.24B |
$1.79B |
21.77% |
| 2013-12-31 |
$8.17B |
$1.80B |
22.03% |
| 2013-09-30 |
$8.05B |
$1.80B |
22.36% |
| 2013-06-30 |
$7.92B |
$2.10B |
26.49% |
| 2013-03-31 |
$7.85B |
$2.13B |
27.09% |
| 2012-12-31 |
$7.78B |
$2.12B |
27.26% |
| 2012-09-30 |
$7.71B |
$2.07B |
26.84% |
| 2012-06-30 |
$7.61B |
$2.05B |
26.90% |
| 2012-03-31 |
$7.58B |
$2.04B |
26.94% |
| 2011-12-31 |
$7.57B |
$2.09B |
27.65% |
| 2011-09-30 |
$7.58B |
$2.16B |
28.48% |
| 2011-06-30 |
$7.34B |
$2.10B |
28.54% |
| 2011-03-31 |
$7.22B |
$2.08B |
28.82% |
| 2010-12-31 |
$7.10B |
$2.06B |
28.98% |
| 2010-09-30 |
$7.12B |
$2.07B |
29.11% |
| 2010-06-30 |
$7.22B |
$2.14B |
29.57% |
| 2010-03-31 |
$7.21B |
$2.13B |
29.58% |
| 2009-12-31 |
$7.14B |
$2.07B |
29.03% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$67.086B |
$19.372B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
